Shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $10.14.
WVE has been the topic of several recent research reports. Leerink Partnrs raised Wave Life Sciences from a "market perform" rating to an "outperform" rating in a research note on Tuesday, December 19th. Truist Financial reissued a "buy" rating and issued a $17.00 price target on shares of Wave Life Sciences in a research note on Monday, April 1st. Royal Bank of Canada reissued a "sector perform" rating and issued a $5.00 price target on shares of Wave Life Sciences in a research note on Thursday, March 7th. HC Wainwright lifted their price target on Wave Life Sciences from $8.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, March 7th. Finally, StockNews.com downgraded Wave Life Sciences from a "strong-buy" rating to a "buy" rating in a research note on Thursday, January 18th.
Read Our Latest Research Report on WVE
Insider Activity at Wave Life Sciences
In related news, CFO Kyle Moran sold 15,630 shares of Wave Life Sciences stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total value of $96,437.10. Following the sale, the chief financial officer now owns 33,921 shares of the company's stock, valued at $209,292.57. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 31.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Wave Life Sciences
A number of institutional investors have recently bought and sold shares of WVE. BlackRock Inc. increased its position in Wave Life Sciences by 1.5% during the first quarter. BlackRock Inc. now owns 2,937,786 shares of the company's stock worth $5,876,000 after buying an additional 43,423 shares during the last quarter. Renaissance Technologies LLC increased its position in Wave Life Sciences by 450.1% during the first quarter. Renaissance Technologies LLC now owns 205,194 shares of the company's stock worth $410,000 after buying an additional 167,894 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Wave Life Sciences by 274.8% during the first quarter. Goldman Sachs Group Inc. now owns 421,412 shares of the company's stock worth $843,000 after acquiring an additional 308,966 shares during the period. Mirabella Financial Services LLP bought a new stake in shares of Wave Life Sciences during the first quarter worth approximately $44,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Wave Life Sciences by 457.0% during the second quarter. BNP Paribas Arbitrage SA now owns 20,777 shares of the company's stock worth $68,000 after acquiring an additional 17,047 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.
Wave Life Sciences Stock Performance
WVE stock traded down $0.20 during midday trading on Friday, hitting $5.80. 647,102 shares of the company's stock were exchanged, compared to its average volume of 885,432. The stock's fifty day moving average price is $5.32 and its 200-day moving average price is $5.24. The company has a market cap of $709.22 million, a PE ratio of -10.55 and a beta of -1.12. Wave Life Sciences has a one year low of $3.15 and a one year high of $7.67.
Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its earnings results on Wednesday, March 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The business had revenue of $29.06 million for the quarter, compared to the consensus estimate of $23.30 million. During the same quarter in the prior year, the firm posted ($0.47) earnings per share. On average, analysts expect that Wave Life Sciences will post -0.94 EPS for the current year.
Wave Life Sciences Company Profile
(
Get Free ReportWave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Further Reading
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
